Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Source: View publication →
The addition of pembrolizumab to first-line platinum-based chemotherapy, with or without bevacizumab, significantly improves overall and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial established a new standard of care for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, providing a transformative therapeutic option that demonstrates durable survival benefits for patients across varying PD-L1 expression levels.
Historical Context
Prior to KEYNOTE-826, treatment options for advanced cervical cancer were limited primarily to platinum-doublet chemotherapy, often combined with bevacizumab based on GOG 240, with historically poor outcomes. The KEYNOTE-826 trial introduced immune checkpoint inhibition into the first-line setting, drastically changing the therapeutic landscape and offering significantly improved life expectancy.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of pembrolizumab in cervical cancer, and why is the Combined Positive Score (CPS) used instead of the Tumor Proportion Score (TPS) as a biomarker?
Key Response
Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells and restoring the anti-tumor immune response. In cervical cancer, the CPS is used because it accounts for PD-L1 expression on both tumor cells and tumor-infiltrating immune cells (macrophages, lymphocytes), which is more representative of the inflamed microenvironment often caused by chronic HPV infection than TPS alone.
In a patient with metastatic cervical cancer and a PD-L1 CPS of 5, how should the results of the KEYNOTE-826 trial influence your selection of first-line therapy compared to the previous GOG 240 standard?
Key Response
Before KEYNOTE-826, the standard was a platinum doublet plus bevacizumab (based on GOG 240). KEYNOTE-826 demonstrated that adding pembrolizumab to this backbone significantly improved both progression-free survival (PFS) and overall survival (OS). For a patient with CPS ≥1, the Hazard Ratio for death was 0.64, making the addition of pembrolizumab the new preferred first-line treatment for patients with PD-L1-positive disease.
Does the survival benefit observed with pembrolizumab in KEYNOTE-826 persist in patients who do not receive concurrent bevacizumab, and how does this impact treatment for those with contraindications to anti-angiogenics?
Key Response
Subgroup analyses in KEYNOTE-826 indicated that the benefit of pembrolizumab was consistent regardless of whether bevacizumab was used. This is clinically significant for patients with contraindications to bevacizumab, such as those with a history of fistulas, uncontrolled hypertension, or major surgery, as they can still achieve superior survival outcomes by adding pembrolizumab to their chemotherapy alone.
With pembrolizumab now established in the first-line setting for metastatic cervical cancer, what are the implications for therapeutic sequencing when a patient progresses, particularly regarding the use of tisotumab vedotin or other immunotherapy agents?
Key Response
Moving pembrolizumab to the first line creates a 'sequencing gap' because prior data for second-line immunotherapy (like KEYNOTE-158) were based on IO-naive patients. Upon progression on first-line pembrolizumab-chemo, practitioners must now look toward agents with different mechanisms, such as the antibody-drug conjugate tisotumab vedotin, as there is currently no evidence that continuing PD-1/PD-L1 inhibition beyond progression or switching to another IO agent is effective in this population.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Evaluate the statistical design of KEYNOTE-826 regarding its dual-primary endpoint strategy and the hierarchical testing across the three PD-L1 CPS populations. How does this design maintain the family-wise error rate?
Key Response
The study utilized a complex graphical method to allocate the type I error (alpha) across the primary endpoints of PFS and OS. Significance was tested sequentially: first in the CPS ≥1 group, then in the CPS ≥10 group, and finally in the all-comers population. This gatekeeping strategy ensures that multiple comparisons across subgroups do not inflate the risk of a false positive finding, ensuring that the results for the all-comer population are statistically valid even though the majority of benefit was driven by PD-L1 positive patients.
How do the 'all-comer' results in KEYNOTE-826 potentially mask the efficacy profile in the PD-L1 negative (CPS <1) subgroup, and is there enough evidence to justify regulatory approval in this specific subset?
Key Response
Approximately 88% of the trial population had a CPS ≥1. While the trial was positive for the 'all-comer' population, a critical reviewer would note that the benefit in the small CPS <1 subgroup was not clearly established and likely did not reach statistical significance independently. This raises concerns about whether 'all-comer' labeling is appropriate or if it simply reflects the overwhelming efficacy in the PD-L1 positive majority, a common point of contention in immunotherapy trials.
Based on KEYNOTE-826, should the recommendation for pembrolizumab + chemotherapy be limited to PD-L1 positive disease, and how does this align with current NCCN and ASCO guidelines?
Key Response
While the FDA-approved label often follows the all-comer data, NCCN and ASCO guidelines specifically emphasize the CPS ≥1 population because that is where the clinical benefit is most robust (Category 1 recommendation). For patients with PD-L1 negative disease (CPS <1), the evidence is less compelling, and guidelines may still suggest the GOG 240 regimen (Chemo + Bevacizumab) alone as an acceptable alternative, highlighting the importance of PD-L1 testing at diagnosis.
Clinical Landscape
Noteworthy Related Trials
GOG 240 Trial
Tested
Paclitaxel and cisplatin or topotecan plus bevacizumab
Population
Persistent, recurrent, or metastatic carcinoma of the cervix
Comparator
Paclitaxel and cisplatin or topotecan without bevacizumab
Endpoint
Overall survival
KEYNOTE-158 Trial
Tested
Pembrolizumab 200 mg every 3 weeks
Population
Previously treated advanced cervical cancer with PD-L1 positive tumors
Comparator
None (single-arm study)
Endpoint
Objective response rate
CheckMate 358 Trial
Tested
Nivolumab 240 mg every 2 weeks
Population
Recurrent or metastatic cervical cancer
Comparator
None (single-arm study)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis